404
Hereditary Angioedema Market Report
Hereditary Angioedema Market Trends, Dynamics & Market Insights
Hereditary Angioedema Market, By Drug Class (C1 Esterase Inhibitor, Kallikrein Inhibitor, Selective Bradykinin B2 Receptor Antagonist), Route of Administration (Intravenous, Subcutaneous Injection, Oral), End-Use (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), and Region ...
The hereditary angioedema market is expected to witness an impressive growth of 7.2% CAGR in the coming years.
Pharming Group NV (Netherlands), Shire plc (US), CSL Limited (Australia), iBio Inc. (US), Bio-Cryst Pharmaceuticals, Inc. (US), Ionis Pharmaceuticals (US), Sanofi S.A. (France), Attune Phar-maceuticals, Inc. (US) and Adverum Biotechnologies, Inc. (US) are among the key players in the hereditary angioedema market.
The hereditary angioedema market size is expected to reach USD 2.8 billion in the foreseeable future.
The hospital pharmacies segment is expected to register significant growth in the hereditary angioedema market in the coming years.
North America accounted for the largest share in the hereditary angioedema market in 2020.
Hereditary angioedema distributors, Hereditary angioedema suppliers, Hereditary angioedema manufacturers, Logistics organizations, Government bodies are the target audience in the hereditary angioedema market.